Press Release : Affimed Announces Presentations at the AACR Annual Meeting 2021
Message : Required fields -- AFM24 preclinical in vivo data will be presented as a poster -- Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that preclinical anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) ) AFM24 have been accepted for e-poster presentation at the American Association for Cancer Research (AA...
Source: marketscreener.com